Skip to main contentSkip to navigation
Sirius Investors
Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

SUPN
NASDAQHealthcare

Revenue Analysis - SUPN

Comprehensive quarterly and annual revenue breakdown by product lines and geographic regions to identify growth drivers and market opportunities.

SUPN Corporation

Annual

Revenue by Product Line

Latest quarterly revenue breakdown by product segments

Quarterly Product Revenue

Product Revenue Details

Detailed breakdown of revenue by product line

Product

0.0% of total revenue

$150.8M

Qelbree

0.0% of total revenue

$77.8M

GOCOVRI

0.0% of total revenue

$35.2M

Royalty, License And Other Revenue

0.0% of total revenue

$29.3M

Collaboration Revenue

0.0% of total revenue

$27.6M

Trokendi Xr

0.0% of total revenue

$9.5M

APOKYN

0.0% of total revenue

$7.7M

Oxtellar X R

0.0% of total revenue

$7.4M

Manufactured Product, Other

0.0% of total revenue

$4.7M

Historical Revenue Data

Quarterly product revenue breakdown over time (Last 6 records)

Date
APOKYN
Collaboration Revenue
GOCOVRI
Manufactured Product, Other
Oxtellar X R
Product
Qelbree
Royalty, License And Other Revenue
Trokendi Xr
3/31/2026$7.7M$27.6M$35.2M$4.7M$7.4M$150.8M$77.8M$29.3M$9.5M
12/31/2025$9.6M$32.8M$38.6M$4.8M$6.8M$158.0M$80.9M$20.7M$8.4M
9/30/2025$10.4M$20.2M$40.8M$7.0M$12.0M$168.5M$81.4M$3.4M$10.0M
6/30/2025$12.8M$0$36.7M$6.5M$11.6M$158.0M$77.5M$7.5M$11.2M
3/31/2025$15.0M$0$30.7M$8.6M$10.2M$142.0M$64.7M$7.8M$12.8M
12/31/2024$37.4M$0$68.6M$14.5M$42.7M$328.9M$133.8M$18.7M$31.9M

Revenue Trend Analysis

Analysis of major growing and declining segments based on recent revenue data

Product Segments

Growing Segments
Royalty, License And Other Revenue+41.4%
Trokendi Xr+13.1%
Declining Segments
APOKYN-19.4%
Collaboration Revenue-15.8%

Earnings Reports

Want to see how SUPN's earnings relate to revenue? View quarterly earnings results, EPS history, and earnings surprises to understand the company's profitability.

View Earnings Reports